Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats
- First Online:
- 307 Downloads
Background and rationale
Nicotinic acetylcholine systems play major roles in cognitive function. Nicotine and a variety of nicotinic agonists improve attention, and nicotinic antagonist exposure impairs it. This study was conducted to investigate the effect of a novel nicotinic receptor agonist at α4β2 nicotinic receptors (AZD3480) on attention and reversal of pharmacologically induced attentional impairment produced by the NMDA glutamate antagonist dizocilpine (MK-801).
Adult female Sprague-Dawley rats were trained to perform an operant visual signal detection task to a stable baseline of accuracy. The rats were then injected subcutaneously following a repeated measures, counter-balanced design with saline, AZD3480 (0.01, 0.1, and 1 mg/kg), dizocilpine (0.05 mg/kg), or their combinations 30 min before the test. The effect of donepezil on the same pharmacologically induced attentional impairment was also tested. A separate group of rats was injected with donepezil (0.01, 0.1, and 1 mg/kg), dizocilpine (0.05 mg/kg), or their combinations, and their attention were assessed. Saline was the vehicle control.
Dizocilpine caused a significant (p < 0.0005) impairment in percent correct performance. This attentional impairment was significantly (p < 0.0005) reversed by 0.01 and 0.1 mg/kg of AZD3480. AZD3480 by itself did not alter the already high baseline control performance. Donepezil (0.01–1.0 mg/kg) also significantly (p < 0.005) attenuated the dizocilpine-induced attentional impairment.
AZD3480, similar to donepezil, showed significant efficacy for counteracting the attentional impairment caused by the NMDA glutamate antagonist dizocilpine. Low doses of AZD3480 may provide therapeutic benefit for reversing attentional impairment in patients suffering from cognitive impairment due to glutamatergic dysregulation and likely other attentional disorders.
KeywordsNicotinic receptors Cognition Nicotinic agonists Dizocilpine MK-801 NMDA α4β2 nicotinic receptors Aricept®
- Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10:147–166PubMedCrossRefGoogle Scholar
- Lippiello PM, Benchierif M, Gray JA, Peters S, Grigoryan G, Hodges H, Collins AC (1996) RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization J Pharmacol Exp Therap 279:1422–1429Google Scholar
- Locke SM, Newhouse PA, Mazzulla E, Wilkins H, Potter AS (2010) Novel nicotinic agonist AZD3480 improves cognition in a randomized control trial of adults with attention-deficit/hyperactivity disorder. Presented at the Society for Neuroscience Annual Meeting, San Diego CA, 13–17 November 2010; Abstract# 563.17Google Scholar
- Rezvani AH, Cauley M, Sexton H, Xiao Y, Brown M, Paige M, McDowell B, Kellar K, Levin ED (2011) Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague Dawley rats. Psychopharmacology 215:621–630PubMedCrossRefGoogle Scholar
- Terry AVJ, Risbrough VB, Buccafusco JJ, Menzaghi F (2002) Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301:284–292PubMedCrossRefGoogle Scholar
- Von Euler G, Bertrand D, Johnson EC (2011) Comparison of pharmacological properties of AZD3480 and AZD1446 on neuronal nicotinic receptor subtypes. Soc Neurosci (Abstract #336.11)Google Scholar
- Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiat 156:1931–1937PubMedGoogle Scholar